Many highly sensitive and elegant assays have been developed which determine enzyme levels in terms of their catalytic activity. The application of such assays to the measurement, in biological fluids, of a wide range of enzymes has proved of immense value in the diagnosis of disease and the monitoring of therapy. It is appropriate, therefore, that clinical enzymology and its exponents now occupy a valued role in most large pathology departments. Nonetheless, the time may have come to question the present emphasis on the measurement of enzymes in terms of their catalytic effects. The continued acceptance of such assays may reflect their relative simplicity and does not exclude the possibility that other analytical techniques may provide clinically relevant information.
The present paper reviews the recent introduction of radioimmunoassay (RIA) for the measurement of enzyme levels in terms of their concentration (Table  1) . It suggests that, while catalytic assays will continue to occupy the predominant role in some situations and that a combination of the two will provide new information in others, measurement of concentration may gradually replace conventional assays for some enzymes in biological fluids.
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CATEGORIES OF ANALYTICAL TECHNIQUES
All analytical procedures can be subdivided into one of three categories (Fig. 1) . The complexity of enzyme molecules precludes their assay by chemical or physical techniques, which are based on specific structural characteristics of the compounds to be assayed. Measurement of the catalytic concentration of an enzyme is a biological assay based on determining the rate of reaction of a substrate that is attributable to the enzyme. Such an assay assesses the functional integrity of the active site of the enzyme, which in turn depends on the conformation (tertiary structure) of the appropriate part of the molecule and may require the presence of activators, such as divalent metals. Bioassays are usually not applicable to the determination of proenzyrnes or the products of enzyme degradation. However, they will usually determine isoenzyrnes from other tissues, the equivalent enzyme from other species and, indeed, related enzymes which may differ considerably in part of their primary structure.
Radioirnmunoassays, which are the subject of this review, are examples of binding assays used to measure the concentration of a ligand (in this instance an enzyme). They employ a specific antibody as the binding protein and isotopically labelled enzyme, as a tracer, to assess the distribution of total enzyme between the antibody-bound and free fractions. It is 
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A few mg of highly purified enzyme are required for use as the standard, for labelling, and for immunisation. Their purification seldom occasions difficulties because of the rigid conformation and relatively high concentration of most enzymes in certain tissues, as well as the applicability of affinity chromatography. Whereas enzymes such as amylase the antibody which determines, in large part, both the sensitivity and specificity of the assay, with the latter depending upon the antigenic determinant-a sequence of some three to five amino acids in the enzyme molecule to which the antibody binds. Such assays will usually determine proenzymes and enzyme breakdown products containing this antigenic determinant as well as the enzyme. They will not usually determine isoenzymes, functionally related enzymes, or the equivalent enzyme from other species.
The results of a bioassay may correlate with those obtained by radioimmunoassay; however, this is not always the case. The finding of different results by a structural (binding assay) and a functional (bioassay) technique does not invalidate either. Two additional points require note. First, each antiserum is unique with regard to its titre, affinity, and antigenic determinant(s). Secondly, immunoassays can be used to determine the rate at which an enzyme is either degrading its substrate or producing a reaction product (Table 2) . Such assays determine biological activity and RIA is used only for endpoint detection. using an antiserum to the hog amylase. Furthermore, Carballo and Troiano (1973) have demonstrated an almost complete lack of cross-reactivity between hog and human elastase. As emphasised above, the most important requirement is a high-titre, high-affinity antiserum which is specific to the enzyme being assayed. There is seldom any difficulty in producing such antisera, since enzymes are very immunogenic. This is because of their rigid conformation and large molecular weight together with the structural differences which exist with similar enzymes in the animals being immunised. Thus, all four rabbits immunised with human pancreatic~amylase produced antisera of acceptable titre and affinity within a few weeks (Fig. 2) . However, large numbers of animals may be required to obtain one antiserum specific for a single isoenzyme.
Isotopically labelled enzyme is essential for use as the tracer. Most groups have employed 125 1 and the chloramine-T method and have experienced difficulties in obtaining a high specific activity product with some enzymes. For example, it proved difficult to 1:5.000 I:40,000 I:20,000 I:10,000 for plasma renin: based on RIA of angiotensin I or angiotensin II for tissue prostaglandin synthetase: based on RIA of PGE produced from arachidonic acid (Bauminger et al., 1973) (8) To Determine Rate of Degradation of a Substrate for plasma angiotensinase: based on RIA of angiotensin I (Strong et al., 1972) for plasma vaspressinase: based on RIA of vasopressin (Rosenbloom et al., 1975) Combine problems of biological assays and of the RIA used for endpoint detection maintain their catalytic activity during isolation procedures, certain others such as the brain isoenzyme of creatine kinase (CK), are partially inactivated during purification (Keutel et al., 1972) . This does not necessarily preclude their use as immunogens, though by preference one should always attempt to maintain enzymic activity and thereby guarantee the integrity of the total tertiary structure; as Sela (1969) has pointed out, "antibodies to native proteins are derived mostly against conformational rather than sequential determinants." However, the state of the active site may be unimportant when immunising because:
(a) The active site epitope(s) constitutes only a small proportion of the many potential immunogenic sites within the protein molecule.
(b) The active site is seldom exposed on the surface of the molecule in the native protein.
(c) Conservation of catalytic activity throughout evolution may require the conservation of the structure of the active site of any enzyme (Cinader, 1968) , thereby making it a poor immunogen.
Because of the specificity of RIA the enzyme must be of appropriate origin with regard to both tissue and species. There is a paucity of pure enzymes of human origin, and one major advantage of the introduction of RIA should be the increased availability of appropriate human standards. Endocrinologists brought up on the dictate that "one must compare like with like" are bemused by the many species and sites of origin of the enzyme preparations currently used for standardisation, which can greatly affect the results obtained. For example, studies in this laboratory have shown that antisera to human pancreatic~amylase do not cross-react with the corresponding commercially available hog enzyme (Langley and Carney, 1976) . This finding is supported by the evidence of Ryan and his colleagues (1975) iodinate human pancreatic (l: amylase but easy to label porcine pancreatic (l: amylase. The reason for this difference remains obscure, but observations on the labelling of ovalbumin may be pertinent (Humphrey, personal communication) . This protein cannot be labelled under standard conditions, using chloramine-T as the oxidant because of the hydrogen bonding of tyrosine residues across the surface of the molecule. This difficulty was overcome by labelling at pH 12.0, and similar modifications may be effective when applied to enzyme labelling. Our experiences in this area are discussed elsewhere (Langley, 1975) .
Even in cases where a high specific radioactivity is achieved during labelling it is often accompanied by a rapid loss of catalytic activity (Kolb and Grodsky, 1971) . In our experience both chloramine-T and lactoperoxidase labelling of brain CK totally destroys enzymic activity, probably by the oxidation of thiol groups necessary for the maintenance of the tertiary structure.
Finally, it is necessary to employ a suitable method to separate the antibody bound and free fractions. The relatively large size of enzymes has for practical purposes limited separation techniques to those based on the use of antibodies conjugated to a solid phase or addition of a second antibody. Attempts to employ methods such as fractional precipitation with neutral salts or organic solvents have usually failed. For example, the use of sodium sulphate to separate free and bound fructose 1,6-diphosphate resulted in the non-specific precipitation of about 20% of free enzyme (Kolb and Grodsky, 1971 ).
DIFFERENCES BETWEEN THE USE OF ENZYME ASSAYS IN BIOCHEMISTRY AND IN CLINICAL

CHEMISTRY
Biochemists have applied enzyme assays predominantly to tissue homogenates in studies of metabolic pathways, rate limiting steps, and enzyme kinetics. It is essential in such situations to determine biological activity. When biochemists moved into the field of clinical chemistry, they naturally employed a similar analytical approach. There is, however, a fundamental difference in that the assays were now predominantly being applied to blood (and urine) rather than tissue homogenates (Table 3) . Such an approach was appropriate for those enzymes that effect their role in the circulation-for example, renin and the enzymes involved in clotting. It was not essential for those enzymes which do not effect their role in the biological fluid, and more than 99 %of the enzyme assays performed in most routine clinical chemistry departments fall into this category. In these situations the enzyme is being employed as a The measurement of enzymes by radioimmunoassay 93 Table 3 . Applications of enzyme assays (A) In-biochemistry: predominantly applied to tissue homogenates to study metabolic pathways, rate-limiting steps, enzyme kinetics, etc. (B) In clinical chemistry: predominantly applied to biological fluids and can be further subdivided into: (a) Enzymes that effect their role in the biological fluid (i.e., renin, enzymes involved in clotting) (b) Enzymes that do not effect their role in the biologicalfluid (i.e., all enzymesdetermined in urine and most in blood) tissue marker, and it is irrelevant whether or not it is biologically active. For those enzymes that effect their role in the biological fluid being assayed additional information may be obtained if an immunoassay is employed to determine their concentration as well as a bioassay to measure their catalytic activity, For example, in a disease associated with the genetic absence of activity of a particular enzyme this combination would enable differentiation between (a) failure to synthesise the enzyme and (b) synthesis of an abnormal form of the enzyme which lacks catalytic activity. For instance in the Lesch-Nyhan syndrome immunoreactive hypoxanthinelguanine phosphoribosyl transferase is present in the tissues of affected individuals, but its enzymic activity is totally lacking (Wyngaarden, 1974) . For the determination of the majority of enzymes which are being used as tissue markers (including, for example, CK in the diagnosis of myocardial infarction or acid phosphatase in a patient with a prostatic neoplasm) either an immunoassay or bioassay could be employed once the relationship between serum concentration and activity has been established.
ADVANTAGES OF ENZYME MEASUREMENT BY CONCENTRATION RATHER THAN BY CATALYTIC
ACTIVITY
Once it is appreciated that the majority of enzyme determinations performed in clinical chemistry are employing the enzyme as a tissue marker and that, therefore, either type of analytical technique may be appropriate, it remains to determine which is preferable. This decision should be based on such standard criteria as sensitivity, specificity, precision, practicability, and diagnostic performance. Thus, while it has been stated that "RIA has a sensitivity beyond the dreams of avarice and a specificity that is almost immoral in this promiscuous era" they take longer to perform and may seem more complex than many simple conventional enzyme assays. (Ryan et al., 1975) Sensitivity RIA provides greater sensitivity than bioassay for those enzymes which have a low catalytic number. Examples are given in Table 4 . This is of practical clinical chemistry (Langley and Carney, 1976) . Each antiserum is unique, and Table 5 , based on the data of Ryan and his colleagues (1975) , shows that their particular antiserum could differentiate porcine pancreatic ex from salivary and other amylases-as demonstrated by the undetectable levels found after pancreatectomy. However, it is unlikely that one could differentiate between all human amylases because, although there are at least two genetic loci for amylase expression, there is only one gene product (Karn et al., 1974) . Differences which are seen in circulating isoenzymes result from post-translational modification of the carbohydrate moiety. Cooper and Foti (1974) Prostatic acid phosphatase Geokas et al. (1974) Pancreatic carboxypeptidase B type II Geiger et al. (1975) Hexosaminidase A or B Specificity showed that their RIA for fructose diphosphatase was much more specific than bioassay, with regard to both the tissue and species of origin of the enzyme. This is not always the case, since in our experience an assay for human pancreatic ex amylase also determines human salivary amylase (Carney, 1976) and pancreatic amylase from several other species, though not that of porcine origin, which is the standard usually employed in importance with regard to the assay of hexosaminidases A and B in the diagnosis of Tay-Sachs disease (Geiger et al., 1975) . Thus the improved sensitivity Table 6 . Examples of use of RIA for isoenzymes of the RIA enables diagnosis at the time of amniocentesis rather than having to culture the amniotic fluid cells some weeks in order to attain levels that can be assayed by the conventional technique.
step, the assay of samples with and without prior heating, or the use of special substrates, etc. There are now grounds to suggest that RIA may prove more specific and in some circumstances simpler than the currently employed procedures.
Practicality
Many factors (Table 7) influence measurement of catalytic concentrations of enzymes. Very different amounts of substrate are reacted at 25°, as compared with 30°or 37°(which comprise some of the recommended temperatures). Indeed, an instrument which fluctuates from its preset temperature by one degree may lead to an error of some 7.5%. Other variables include the identity and concentration of the substrate, of coenzymes (such as NAD and pyridoxal phosphate), and of activators (such as the divalent metals, magnesium and zinc). The hydrogen ion concentration and ionic strength of the reaction mixture markedly influence results, as may the presence of enzyme inhibitors in the sample (drugs, anticoagulant, urea, oxalate, specific inhibitors), in reagents including water, on the glassware, or in the reaction mixture (for example, the products of the reaction). The concentration of enzymes employed in indicator and/or auxiliary reactions for coupled systems must be optimal. Finally, the assay should be based on the initial linear first-order reaction rate (which necessitates sophisticated equipment to enable continuous or multipoint monitoring), and care must be taken with choice of cuvettes or the use of haemolysed, pigment-containing or lipaemic samples which may effect endpoint detection. It is hardly surprising, therefore, that The measurement of enzymes by radioimmunoassay 95 difficulties are experienced in ensuring reproducibility of results "within" and "between" laboratories and in recommending internationally accepted methods.
RIA is less affected by many of these factors (Kolb, 1974) , and, of particular importance, immunoassays appear able to determine enzyme levels in the presence of inhibitors. Thus, while it has been stated that "naturally occurring inhibitors in serum do not seem to be present in concentrations high enough to have a significant influence on the in vitro assay of enzymes" (Mattenheimer, 1972) , there is now sufficient evidence in the literature to refute this statement. Indeed, one use of a combination of bioassay and immunoassay is to determine accurately the levels of some inhibitors and thereby assess whether they playa role in disease.
Among the most elegant demonstrations of the effects of inhibitors are those by Temler and Felber (1974) . In one study (Table 8) they obtained similar   Table 8 . Porcine trypsin levels (lJg/m/) in buffer and plasma (Tembler and Felber, 1974) In buffer
In 1 porcine trypsin levels in buffer, using the two analytical techniques, whereas there was a complete loss of biological activity after the addition of plasma, which did not affect the RIA. Temler and Felber (l97l) also showed ( Fig. 3 ) that the addition of aprotinin (Trasylol) or DFP impaired the catalytic activity of trypsin without significantly affecting its immunological activity. A further example of such a dissociation was provided by Carbello and his colleagues (1974) , who showed that the induction of acute pancreatitis in dogs resulted in a rapid and marked rise in plasma elastase levels, as determined by RIA, but an immediate fall, as determined by bioassay. They concluded that this discrepancy was probably due to activation or augmentation of circulating enzyme inhibitors.
In contrast a direct linear relationship has been demonstrated, in our laboratory between serum amylase concentration and activity, even during an attack of acute pancreatitis ( 
RIA Serum Levels ofProteteolytic Enzymes
Until recently it was uncertain whether the apparent absence of certain proteolytic enzymes, such as pancreatic trypsin, in serum samples reflected their failure to enter the circulation or the presence of inhibitors which prevented their determination by catalytic assays. It is now known that the latter is correct and the development of RIA to determine serum levels of such enzymes opens up new and exciting possibilities in, for example, gastroenterology. This is illustrated by the work of Samloff and Liebman (1974) , who developed and applied a specific RIA for the group 1 pepsinogens-which enabled excellent differentiation between control subjects and fragments, and measurement of serum amylase activity provides therefore a direct assessment of concentration. Nonetheless, in view of the unreliable nature of many of the activity assays in routine clinical use for amylase it is possible that RIA may become the method of choice. To establish, with certainty, whether the patient has had an infarction; its extent and evidence of further infarction.
Criteria for Suitable Marker
1. Normally undetectable in circulation 2. Specific for myocardial destruction not being released due to increased permeability not present in other tissues 3. Circulating levels related directly to size of infarction and reflecting further progression. Its clearance from the circulation should, therefore, be unaffected by renal, hepatic or other disorders. 4. Availability of an extremely sensitive, precise analytical technique. Release of the marker should be specific to the tissue being assessed and also to the type of lesion. Thus it should not be present in tissues other than the heart, nor should it be released as a result of increased membrane permeability, but only if cellular destruction has occurred.
Assays based on the catalytic activity of enzymes have so far failed to meet these criteria and also fail to determine the presence of proenzyrnes, enzyme subunits, or enzyme fragments despite the fact that these would be equally effective markers.
An RIA has been developed for the MM isoenzyme of CK, but it does not differentiate between skeletal muscle damage and myocardial damage because this isoenzyme is common to both tissues (Nicholson and O'Sullivan, 1973) . Other workers have raised antibodies to the MM and BB isoenzymes and used them in enzyme inhibition imrnunoassays to measure the heart specific MB isoenzyme (Jockers-Wretou and Pfleiderer, 1975) . The crossreactivity between the MB isoenzyme and antisera raised against the MM and BB isoenzymes, which forms the basis of the assay would suggest that it may prove extremely difficult to produce an antiserum It can be argued that the continued use of catalytic assays in the above and in related situations illustrates the general maxim that "thought is dominated by existing methodology rather than existing methodology by thought". Since these enzymes are being employed as tissue markers it is more appropriate to assess first the criteria for a suitable marker (Table  9 ). Early diagnosis is greatly facilitated if the marker is not normally detectable in the circulation and an extremely sensitive and precise analytical technique is employed. those with pernicious anaemia or after total gastrectomy on the one hand and patients with the Zol1inger-Ellison syndrome on the other. An RIA for human pancreatic carboxypeptidases B, by Geokas and his colleagues (1974) differentiated between patients with acute pancreatitis and control subjects. Of more importance, the assay could be employed as the basis of a dynamic test of pancreatic function (Fig. 5) to determine the serum carboxypeptidase response to the injection of secretin.
Enzyme Determinations for the Diagnosis of Myocardial Infarction
The determination of serum levels of aspartate aminotransferase (AST), of lactic dehydrogenase (LDH), and of creatine phosphokinase (CK) has proved of value in the diagnosis of myocardial infarction. More recent developments include the assay of the LDH isoenzyme 1 and 2 employing, for example, 2-oxobutyrate as substrate, and the assay of the MB fraction of CK by a procedure which usually involves initial separation of the MB and MM fractions by column chromatography. totally specific for MB. Hence, an RIA to detect CK release from damaged myocardium should probably be based on the use of an antiserum to the BB isoenzyme which cross-reacts with the B subunit present in the cardiac hybrid. However, earlier beliefs that BB was virtually absent from the circulation have recently been challenged (Byrnes and Sheldon, 1975) . While RIA may resolve this issue, the presence of basal BB levels in samples might complicate interpretation. Another approach would be to establish an RIA specific for the AsT isoenzyme of the mitochondria (Mito-GOT) as opposed to that found in cytoplasm (Cyto-GOT) to avoid the problem of increased membrane permeability.
Such approaches, however, reflect the natural tendency to continue along established pathways. Since a catalytically active enzyme is no longer required for the analysis, one can employ an RIA for chosen specific myocardial protein, not necessarily an enzyme or an enzyme subunit. This would be analogous to the RIA being developed for specific fetal or placental proteins for the assessment of feto-placental well-being or for tumour associated proteins. A concerted effort to establish irnmunoassays for specific myocardial, renal, hepatic, and other tissue proteins (in preference to enzyme assays) could well yield dividends in clinical chemistry.
CONCLUSIONS
The present paper first emphasised the difference between catalytic assays for enzymes, which assess function, and immunoassays which assess structure. More than 40 papers relating to the determination of enzyme levels by their concentration had been published by the end of 1975 and these have been reviewed. Based on these data a case has been advanced: (a) that bioassays will remain the technique of choice in clinical chemistry for those enzymes such as plasmin which effect their physiological role in the biological fluid in which they are being determined; (2) that the combination of bioassay and immunoassay may prove of value in many basic biochemical studies; and (3) that immunoassays may partially and gradually replace catalytic enzyme assays for the many enzymes which do not effect their physiological role in the biological fluid in which they are being determined. Such assays will have particular relevance for isoenzymes and for those enzymes for which circulating inhibitors exist. Finally, it is possible that this approach will enable the development of assays for tissues markers other than enzymes.
